Endothelium-targeted pharmacotherapeutics for the treatment of stroke

Current Opinion in Investigational Drugs

Volumn 3, Issue 6, 2002, Pages 896-904

  Danton, Gary ^a   Watson, Brant D ^a   Prado, Ricardo ^a   Dietrich, W Dalton ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Animal model; Cerebrovascular disorder; Endothelium; Vascular pharmacotherapy

Indexed keywords

4 ANILINO 5 PHENYLPYRROLO[2,3 D]PYRIMIDINE 7 (5 DEOXYRIBOSIDE); 5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; 6,7,8,9 TETRAHYDRO 9 (2 MORPHOLINOETHYL) 2,4 BIS(1 PYRROLIDINYL) 5H PYRIMIDO[4,5 B]INDOLE; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ADENOSINE RECEPTOR STIMULATING AGENT; ATORVASTATIN; BATIMASTAT; BB 1101; CLOPIDOGREL; DIPYRIDAMOLE; DISUFENTON SODIUM; EMOPAMIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KB R 7785; KETANSERIN; MATRIX METALLOPROTEINASE INHIBITOR; MDL 74180DA; MK 186; N [2 [4 (5H DIBENZO[A,D]CYCLOHEPTEN 5 YLIDENE)PIPERIDINO]ETHYL] 1 FORMYLISONIPECOTAMIDE; NICARAVEN; NORPHENAZONE; PRAVASTATIN; PROPENTOFYLLINE; RITANSERIN; SARPOGRELATE; SCAVENGER; SEREFREV; SEROTONIN ANTAGONIST; TICLOPIDINE; TIRILAZAD; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BLOOD BRAIN BARRIER; BRAIN BLOOD FLOW; BRAIN HEMORRHAGE; BRAIN INFARCTION; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE MODEL; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EXPERIMENTAL MODEL; HUMAN; LIVER TOXICITY; META ANALYSIS; MUSCULOSKELETAL DISEASE; NEWBORN; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SIDE EFFECT; STROKE; THROMBOEMBOLISM; VASCULAR ENDOTHELIUM;

ADENOSINE; ANIMALS; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; FREE RADICAL SCAVENGERS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MATRIX METALLOPROTEINASES; SEROTONIN ANTAGONISTS; VASODILATOR AGENTS;

EID: 0036628395     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (111)

1. Del Zoppo GJ: Why do all drugs work in animals but none in stroke patients? 1. Drugs promoting cerebral blood flow. J Intern Med (1995) 237(1):79-88.
2. Grotta J: Why do all drugs work in animals but none in stroke patients? 2. Neuroprotective therapy. J Intern Med (1995) 237(1):89-94.
3. Kuluz JW, Prado RJ, Dietrich WD, Schleien CL, Watson BD: The effect of nitric oxide synthase inhibition on infarct volume after reversible focal cerebral ischemia in conscious rats. Stroke (1993) 24(12):2023-2029.
4. Morikawa E, Ginsberg MD, Dietrich WD, Duncan RC, Kraydieh S, Globus MY, Busto R: The significance of brain temperature in focal cerebral ischemia: Histopathological consequences of middle cerebral artery occlusion in the rat. J Cereb Blood Flow Metab (1992) 12(3):380-389.
5. 2 antagonist, sarpogrelate hydrochloride, shows inhibitory effects on both contraction and relaxation mediated by 5-HT receptor subtypes in porcine coronary arteries. Pharmacology (2000) 61(4):263-368.
6. Mikawa K, Akamatsu H, Nishina K, Shiga M, Maekawa N, Obara H, Niwa Y: The effects of sarpogrelate on superoxide production by human neutrophils. Reg Anesth Pain Med (2000) 25(2):181-186.
7. Zivin JA, Fisher M, DeGirolami U, Hemenway CC, Stashak JA: Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science (1985) 230(4731):1289-1292.
8. Gunning AJ, Pickering GW, Robb-Smith AH, Russell RR: Mural thrombosis of the internal carotid artery and subsequent embolism. Quart J Med (1964) Jan:155-195.
9. Bourgain RH, Vermarien H, Andries R, Vereecke F, Jacqueloot J, Rennies J, Blockeel E, Six F: A standardized 'in vivo' model for the study of experimental arterial thrombosis: Description of a method. Adv Exp Med Biol (1984) 180:635-649.
10. Watson BD, Dietrich WD, Busto R, Wachtel MS, Ginsberg MD: Induction of reproducible brain infarction by photochemically initiated thrombosis. Ann Neurol (1985) 17(5):497-504.
11. Futrell N, Watson BD, Dietrich WD, Prado R, Millikan C, Ginsberg MD: A new model of embolic stroke produced by photochemical injury to the carotid artery in the rat. Ann Neurol (1988) 23(3):251-257.
12. Morikawa E, Moskowitz MA, Huang Z, Yoshida T, Irikura K, Dalkara T: L-arginine infusion promotes nitric oxide-dependent vasodilation, increases regional cerebral blood flow, and reduces infarction volume in the rat. Stroke (1994) 25(2):429-435.
13. Prado R, Watson BD, Zhao W, Yao H, Busto R, Dietrich WD, Ginsberg MD: L-arginine does not improve cortical perfusion or histopathological outcome in spontaneously hypertensive rats subjected to distal middle cerebral artery photothrombotic occlusion. J Cereb Blood Flow Metab (1996) 16(4):612-622.
14. Dietrich WD, Kraydieh S, Prado R, Stagliano NE: White matter alterations following thromboembolic stroke: A β-amyloid precursor protein immunocytochemical study in rats. Acta Neuropathol (Berl) (1998) 95:524-531.
15. Dietrich WD, Prado R, Watson BD, Busto R, Ginsberg MD: Hemodynamic consequences of common carotid artery thrombosis and thrombogenically activated blood in rats. J Cereb Blood Flow Metab (1991) 11(6):957-965.
16. Dietrich WD, Danton G, Hopkins AC, Prado R: Thromboembolic events predispose the brain to widespread cerebral infarction after delayed transient global ischemia in rats. Stroke (1999) 30(4):855-861; discussion 862.
17. Danton GH, Prado R, Watson BD, Dietrich WD: Temporal profile of enhanced vulnerability of the post-thrombotic brain to secondary embolic events. Stroke (2002) 33(4):1113-1119.
18. Wester P, Dietrich WD, Prado R, Watson BD, Globus MY: Serotonin release into plasma during common carotid artery thrombosis in rats. Stroke (1992) 23(6):870-875.
19. Cohen Z, Bonvento G, Lacombe P, Hamel E: Serotonin in the regulation of brain microcirculation. Prog Neurobiol (1996) 50(4):335-362.
20. 2 type. Biochem Pharmacol (1983) 32(3):567-570.
21. Qi R, Ozaki Y, Satoh K, Kurota K, Asazuma N, Yatomi Y, Kume S: Quantitative measurement of various 5-HT receptor antagonists on platelet activation induced by serotonin. Thromb Res (1996) 81(1):43-54.
22. Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, Panak E, Roberts RS, Sicurella J, Turpie AG: The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet (1989) 1(8649):1215-1220.
23. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A: European Stroke Prevention Study. 2. Dipyridamole and acetylsalicyclic acid in the secondary prevention of stroke. J Neurol Sci (1996) 143(1-2):1-13.
24. Mayhan WG, Faraci FM, Heistad DD: Responses of cerebral arterioles to adenosine 5′-diphosphate, serotonin, and the thromboxane analogue U-46619 during chronic hypertension. Hypertension (1988) 12(6):556-561.
25. Lamping KG, Faraci FM: Role of sex differences and effects of endothelial NO synthase deficiency in responses of carotid arteries to serotonin. Arterioscler Thromb Vasc Biol (2001) 21(4):523-528.
26. White RP, Markus HS: Impaired dynamic cerebral upregulation in carotid artery stenosis. Stroke (1997) 28(7):1340-1344.
27. 2 to acetazolamide. J Cereb Blood Flow Metab (1992) 12(1):162-168.
28. Gu AY, Bova I, Bornstein NM: Is impaired cerebral vasomotor reactivity a predictive factor of stroke in asymptomatic patients? Stroke (1996) 27 (12):2188-2190.
29. Chollet F, Celsis P, Clanet M, Guiraud-Chaumeil B, Rascol A, Marc-Vergnes JP: SPECT study of cerebral blood flow reactivity after acetazolamide in patients with transient ischemic attacks. Stroke (1989) 20(4):458-464.
30. Markus H, Cullinane M: Severely impaired cerebrovascular reactivity predicts stroke and TIA risk in patients with carotid artery stenosis and occlusion. Brain (2001) 124(Pt 3):457-467.
31. Hara H, Kitajima A, Shimada H, Tamao Y: Antithrombotic effect of MCI-9042, a new antiplatelet agent on experimental thrombosis models. Thromb Haemost (1991) 66(4):484-488.
32. Dietrich WD, Busto R, Ginsberg MD: Effect of the serotonin antagonist ketanserin on the hemodynamic and morphological consequences of thrombotic infarction. J Cereb Blood Flow Metab (1989) 9(6):812-820.
33. Globus MY, Wester P, Busto R, Dietrich WD: Ischemia-induced extracellular release of serotonin plays a role in CA1 neuronal cell death in rats. Stroke (1992) 23(11):1595-1601.
34. 2 receptor antagonist, increases subcortical blood flow following photothrombotic middle cerebral artery occlusion in rats. Neurol Res (1998) 20(7):643-647.
35. 2 receptor antagonist, on ischemic cerebral blood flow and infarct volume in rat middle cerebral artery occlusion. Stroke (1994) 25(2):481-485; discussion 485-486.
36. Shouzu A, Nomura S, Hayakawa T, Omoto S, Shimizu H, Miyake Y, Yonemoto T,Fukuhara S, Iwasaka T, Nishikawa M, Inada M: Effect of sarpogrelate hydrochloride on platelet-derived microparticles and various soluble adhesion molecules in diabetes mellitus. Clin Appl Thromb Hemost (2000) 6(3):139-143.
37. Prevention of atherosclerotic complications: Controlled trial of ketanserin. Prevention of Atherosclerotic Complications with Ketanserin Trial Group. Br Med J (1989) 298:424-430.
38. 1 receptor antagonist. J Cereb Blood Flow Metab (2002) 22(2):161-170.
39. Dietrich WD, Miller LP, Prado R, Dewanjee S, Alexis N, Dewanjee MK, Gruber H: Acadesine reduces indium-labeled platelet deposition after prothrombosis of the common carotid artery in rats. Stroke (1995) 26(1):111-116.
40. Turcani P, Tureani M: Effect of propentofylline on cerebral blood flow in a gerbil focal cerebral ischemia. J Neurol Sci (2001) 183(1):57-60.
41. 2A receptor antagonist and antagonist. Eur J Pharmacol (1995) 287(3):295-302.
42. Tatlisumak T, Takano K, Carano RA, Miller LP, Foster AC, Fisher M: Delayed treatment with an adenosine kinase inhibitor, GP683, attenuates infarct size in rats with temporary middle cerebral artery occlusion. Stroke (1998) 29(9):1952-1958.
43. Mullane K, Bullough D, Shapiro D: From academic vision to clinical reality: A case study. Trends Cardiovasc Med (1993) 3:227-234.
44. Picano E, Abbracchio MP: European Stroke Prevention Study-2 results: Serendipitous demonstration of neuroprotection induced by endogenous adenosine accumulation? Trends Pharmacol Sci (1998) 19(1):14-16.
45. Heidland UE, Heintzen MP, Michel CJ, Strauer BE: Effect of adjunctive intracoronary adenosine on myocardial ischemia, hemodynamic function and left ventricular performance during percutaneous transluminal coronary angioplasty: Clinical access to ischemic preconditioning? Coron Artery Dis (2000) 11(5):421-428.
46. Mahaffey KW, Puma JA, Barbagelata NA, DiCarli MF, Leesar MA, Browne KF, Eisenberg PR, Bolli R, Casas AC, Molina-Viamonte V, Orlandi C, Blevins R, Gibbons RJ, Califf RM, Granger CB: Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: Results of a multicenter, randomized, placebo-controlled trial: The Aute Myocardial Infarction Study of Adenosine (AMISTAD) trial. J Am Coll Cardiol (1999) 34(6):1711-1720.
47. Nelson CW, Wei EP, Povlishock JT, Kontos HA, Moskowitz MA: Oxygen radicals in cerebral ischemia. Am J Physiol (1992) 263(5 Pt 2):H1356-H1362.
48. Beckman JS, Koppenol WH: Nitric oxide, superoxide, and peroxynitrite: The good, the bad, and ugly. Am J Physiol (1996) 271 (5 Pt 1):C1424-C1437. A good review of nitric oxide and free radical reactions.
49. Kontos HA: Oxygen radicals in cerebral ischemia: The 2001 Willis lecture. Stroke (2001) 32(11):2712-2716. An excellent review of free radical reactons and their importance following ischemia.
50. Kim GW, Lewin A, Copin J, Watson BD, Chan PH: The cytosolic antioxidant, copper/zinc superoxide dismutase, attenuates blood-brain barrier disruption and oxidative cellular injury after prothrombotic cortical ischemia in mice. Neuroscience (2001) 105(4):1007-1018.
51. Kogure K, Watson BD, Busto R, Abe K: Potentiation of lipid peroxides by ischemia in rat brain. Neurochem Res (1982) 7(4):437-454.
52. Toyoda T, Kassell NF, Lee KS: Attenuation of ischemia-reperfusion injury in the rat neocortex by the hydroxyl radical scavenger nicaraven. Neurosurgery (1997) 40(2):372-377; discussion 377-378.
53. Hall ED, Andrus PK, Smith SL, Oostveen JA, Scherch HM, Lutzke BS, Raub TJ, Sawada GA, Palmer JR, Banitt LS, Tustin JS, Belonga KL, Ayer DE, Bundy GL: Neuroprotective efficacy of microvascularly-localized versus brain- penetrating antioxidants. Acta Neurochir Suppl (1996) 66:107-113. Describes a variety of novel lazaroids that may be more effective than tirilazad.
54. Nishi H, Watanabe T, Sakurai H, Yuki S, Ishibashi A: Effect of MCI-186 on brain edema in rats. Stroke (1989) 20(9):1236-1240.
55. Kuroda S, Tsuchidate R, Smith ML, Maples KR, Siesjo BK: Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat. J Cereb Blood Flow Metab (1999) 19(7):778-787.
56. Cao X, Phillis JW: α-phenyl-tert-butyl-nitrone reduces cortical infarct and edema in rats subjected to focal ischemia. Brain Res (1994) 644(2):267-272.
57. Marshall JW, Duffin KJ, Green AR, Ridley RM: NXY-059, a free radical-trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species. Stroke (2001) 32(1):190-198.
58. Muizelaar JP, Marmarou A, Young HF, Choi SC, Wolf A, Schneider RL, Kontos HA: Improving the outcome of severe head injury with the oxygen radical scavenger polyethylene glycol-conjugated superoxide dismutase: A phase II trial. J Neurosurg (1993) 78(3):375-382.
59. Tirilazad mesylate in acute ischemic stroke: A systematic review. Tirilazad International Steering Committee. Stroke (2000) 31(9):2257-2265.
60. Duffy SJ, Biegelsen ES, Holbrook M, Russell JD, Gokce N, Kearney JF Jr, Vita JA: Iron chelation improves endothelial function in patients with coronary artery disease. Circulation (2001) 103(23):2799-2804.
61. Rosenberg GA, Estrada EY, Dencoff JE: Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke (1998) 29(10):2189-2195.
62. Romanic AM, White RF, Arleth AJ, Ohlstein EH, Barone FC: Matrix metalloproteinase expression increases after cerebral focali ischemia in rats: Inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke (1998) 29(5):1020-1030. MMP-9 and -2 activity and protein content determined by Western blot analysis and immunohistochemistry increase after ischemia and are associated with inflammatory cells.
63. Montaner J, Alvarez-Sabin J, Molina C, Angles A, Abillera S, Arenillas J, Gonzalez MA, Monasterio J: Matrix metalloproteinases expression after human cardioembolic stroke: Temporal profile and relation to neurological impairment. Stroke (2001) 32(8):1759-1766. Interesting correlation between MMP-9 expression and outcome after human stroke.
64. Montaner J, Alvarez-Sabin J, Molina CA, Angles A, Abilleira S, Arenillas J, Monasterio J: Matrix metalloproteinases expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke (2001) 32(12):2762-2767. Interesting correlation between MMP-9 expression and hemorrhagic transformation in patients.
65. Asahi M, Asahi K, Jung JC, Del Zoppo GJ, Fini ME, Lo EH: Role for matrix metalloproteinase 9 after focal cerebral ischemia: Effects of gene knockout and enzyme inhibition with BB-94. J Cereb Blood Flow Metab (2000) 20(12):1681-1689.
66. Jiang X, Namura S, Nagata I: Matrix metalloproteinase inhibitor KB-R7785 attenuates brain damage resulting from permanent focal cerebral ischemia in mice. Neurosci Lett (2001) 305(1):41-44.
67. Lapchak PA, Chapman DF, Zivin JA: Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke (2000) 31(12):3034-3040.
68. Sumii T, Lo EH: Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke (2002) 33(3):831-836.
69. Hidalgo M, Eckhardt SG: Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst (2001) 93(3):178-193.
70. Di Mascio R, Marchioli R, Tognoni G: Cholesterol reduction and stroke occurrence: An overview of randomized clinical trials. Cerebrovasc Dis (2000) 10(2):85-92.
71. Blauw GJ, Lagaay AM, Smelt AH, Westendorp RG: Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke (1997) 28(5):946-950. Good overview of various stroke trials.
72. Gorelick PB, Sacco RL, Smith DB, Alberts M, Mustone-Alexander L, Rader D, Ross JL, Raps E, Ozer MN, Brass LM, Malone ME, Goldberg S, Booss J, Hanley DF, Toole JF, Greengold NL, Rhew DC: Prevention of a first stroke: A review of guidelines and a muldisciplinary consensus statement from the National Stroke Association. J Am Med Assoc (1999) 281(12):1112-1120.
73. Szucs TD: Pharmaco-economic aspects of lipid-lowering therapy: Is it worth the price? Eur Heart J (1998) 19(Suppl M):M22-M28. Cost-analysis is an important aspect of modern medicine.
74. Chong PH, Seeger JD, Franklin C: Clinically relevant differences between the statins: Implications for therapeutic selection. Am J Med (2001) 111(5):390-400.
75. Vaughan CJ, Delanty N: Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke (1999) 30(9):1969-1973.
76. Delanty N, Vaughan CJ: Vascular effects of statins in stroke. Stroke (1997) 28(11):2315-2320. A short and easy to read review of statins.
77. Puddu P, Puddu GM, Muscari A: HMG-CoA reductase inhibitors: Is the endothelium the main target? Cardiology (2001) 95(1):9-13. Cites experimental and clinical studies that suggest an endothelial effect of statins.
78. Sessa WC: Can modulation of endothelial nitric oxide synthase explain the vasculoprotective actions of statins? Trends Mol Med (2001) 7(5):189-191.
79. Mayer J, Eller T, Brauer P, Solleder EM, Schafer RM, Keller F, Kochsiek K: Effects of long-term treatment with lovastatin on the clotting system and blood platelets. Ann Hematol (1992) 64(4):196-201.
80. Amin-Hanjani S, Stagliano NE, Yamada M, Huang PL, Liao JK, Moskowitz MA: Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke (2001) 32(4):980-986.
81. O'Driscoll G, Green D, Taylor RR: Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function with 1 month. Circulation (1997) 95(5):1126-1131.
82. Sumi D, Hayashi T, Thakur NK, Jayachandran M, Asai Y, Kano H, Matsui H, Iguchi A: A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects- the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action. Atherosclerosis (2001) 155(2):347-357.
83. Rikitake Y, Kawashima S, Takeshita S, Yamashita T, Azumi H, Yasuhara M, Nishi H, Inoue N, Yokoyama M: Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis (2001) 154(1):87-96.
84. Bellosta S, Via D, Canavesi M, Pfister P, Fumagalli R, Paoletti R, Bernini F: HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol (1998) 18(11):1671-1678.
85. Wilson SH, Hermann J, Lerman LO, Holmes DR Jr, Napoli C, Ritman EL, Lerman A: Simvastatin preserves the structure of coronary adventitial vasa vasorum in experimental hypercholesterolemia independent of lipid lowering. Circulation (2002) 105(4):415-418.
86. Clement DL, Duprez D: Effect of ketanserin in the treatment of patients with intermittent claudication: Results from 13 placebo-controlled parallel group studies. J Cardiovasc Pharmacol (1987) 10(Suppl 3):S89-S95.
87. Lin BW, Dietrich WD, Busto R, Ginsberg MD: (S)-emopamil protects against global ischemic brain injury in rats. Stroke (1990) 21(12):1734-1739.
88. Nakayama H, Ginsberg MD, Dietrich WD: (S)-emopamil, a novel calcium channel blocker and serotonin S2 antagonist, markedly reduces infarct size following middle cerebral artery occlusion in the rat. Neurology (1988) 38(11):1667-1673.
89. 2A receptor antagonist, in rat arterial thrombosis model and its effect on bleeding mice. Eur J Pharmacol (2001) 433(2-3):157-162.
90. Miller LP, Jelovich LA, Yao L, DaRe J, Ugarkar B, Foster AC: Pre- and peristroke treatment with the adenosine kinase inhibitor, 5′-deoxyiodotubercidin, significantly reduces infarct volume after temporary occlusion of the middle cerebral artery in rats. Neurosci Lett (1996) 220(2):73-76.
91. Lapchak PA, Chapman DF, Zivin JA: Pharmacological effects of the spin trap agents N-t-butyl-phenylnitrone (PBN) and 2,2,6, 6-tetramethylpiperidine-N-oxyl (TEMPO) in a rabbit thromboembolic stroke model: Combination studies with the thrombolytic tissue plasminogen activator. Stroke (2001) 32(1):147-153.
92. Asahi M, Asahi K, Wang X, Lo EH: Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats. J Cereb Blood Flow Metab (2000) 20(3):452-457.
93. Nakashima M, Niwa M, Iwai T, Uematsu T: Involvement of free radicals in cerebral vascular reperfusion injury evaluated in a transient focal cerebral ischemia model of rat. Free Radic Biol Med (1999) 26(5-6):722-729.
94. Yang Y, Li Q, Shuaib A: Neuroprotection by 2-h postischemia administration of two free radical scavengers, α-phenyl-n-tert-butyl-nitrone (PBN) and N-tert-butyl-(2-sulfophenyl)-nitrone (S-PBN), in rats subjected to focal embolic cerebral ischemia. Exp Neurol (2000) 163(1):39-45.
95. Pazos AJ, Green EJ, Busto R, McCabe PM, Baena RC, Ginsberg MD, Globus MY, Schneiderman N, Dietrich WD: Effects of combined postischemic hypothermia and delayed N-tert-butyl-α-phenylnitrone (PBN) administration on histopathologicaland behavioral deficits associated with transient global ischemia in rats. Brain Res (1999) 846(2):186-195.
96. Mizuno A, Umemura K, Nakashima M: Inhibitory effect of MCI-186, a free radical scavenger, on cerebral ischemia following rat middle cerebral artery occlusion. Gen Pharmacol (1998) 30(4):575-578.
97. Kawai H, Nakai H, Suga M, Yuki S, Watanabe T, Saito KI: Effects of a novel free radical scavenger, MCI-186, on ischemic brain damage in the rat distal middle cerebral artery occlusion model. J Pharmacol Exp Ther (1997) 281(2):921-927.
98. Sydserff SG, Borelli AR, Green AR, Cross AJ: Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; Studies on dose, plasma concentration and therapeutic time window. Br J Pharmacol (2002) 135(1):103-112.
99. Lees KR, Sharma AK, Barer D, Ford GA, Kostulas V, Cheng YF, Odergren T: Tolerability and pharmacokinetics of the nitrone NXY-059 in patients with acute stroke. Stroke (2001) 32(3):675-680.
100. Truelove D, Shuaib A, Ijaz S, Ishaqzay R, Kalra J: Neuronal protection with superoxide dismutase in repetitive forebrain ischemia in gerbils. Free Radic Biol Med (1994) 17(5):445-450.
101. Zhang XM, Ellis EF: Superoxide dismutase reduces permeability and edema induced by hypertension in rats. Am J Physiol (1990) 259(2 Pt 2):H497-H503.
102. Xue D, Slivka A, Buchan AM: Tirilazad reduces cortical infarction after transient but not permanent focal cerebral ischemia in rats. Stroke (1992) 23(6):894-899.
103. Kassell NF, Haley EC, Apperson-Hansen C, Alves WM: Randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: A cooperative study in Europe, Australia, and New Zealand. J Neurosurg (1996) 84(2):221-228.
104. Cowley DJ, Lukovic L, Petty MA: MDL 74,180 reduces cerebral infarction and free radical concentrations in rats subjected to ischaemia and reperfusion. Eur J Pharmacol (1996) 298(3):227-233.
105. Asano T, Takakura K, Sano K, Kikuchi H, Nagai H, Saito I, Tamura A, Ochiai C, Sasaki T: Effects of a hydroxyl radical scavenger on delayed ischemic neurological deficits following aneurysmal subarachnoid hemorrhage: Results of a multicenter, placebo-controlled double-blind trial. J Neurosurg (1996) 84(5):792-803.
106. 4S reduces cerebral ischemia-induced infarct volume in gerbils. Neurosci Lett (2001) 311(2):121-124.
107. Huang SS, Tsai SK, Chih CL, Chiang LY, Hsieh HM, Teng CM, Tsai MC: Neuroprotective effect of hexasulfobutylated C60 on rats subjected to focal cerebral ischemia. Free Radic Biol Med (2001) 30(6):643-649.
108. Beaulieu C, Busch E, Rother J, De Crespigny A, Hsia CJ, Moseley ME: Polynitroxyl albumin reduces infarct size in transient focal cerebral ischemia in the rat: Potential mechanisms studied by magnetic resonance imaging. J Cereb Blood Flow Metab (1998) 18(9):1022-1031.
109. Laufs U, Gertz K, Huang P, Nickenig G, Bohm M, Dirnagl U, Endres M: Atorvastatin upregulates type III nitric oxide synthase in cerebral ischemia in normocholesterolemic mice. Stroke (2000) 31(10):2442-2449.
110. Hunt D, Young P, Simes J, Hague E, Mann S, Owensby D, Lane G, Tonkin A: Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial. Ann Intern Med (2001) 134(10):931-940.
111. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, Liao JK: Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA (1998) 95(15):8880-8885.